The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE). It requires upgrading AstraZeneca's existing U.S. equity listing by way of a direct listing of AstraZeneca ordinary shares on the NYSE, replacing the existing U.S. listing of AstraZeneca ADRs on Nasdaq, the company said in a press release on Monday. Following the i ...